Compounds > moxifloxacin
Page last updated: 2024-09-04

moxifloxacin and efavirenz

moxifloxacin has been researched along with efavirenz in 6 studies

Compound Research Comparison

Studies
(moxifloxacin)		Trials
(moxifloxacin)		Recent Studies (post-2010)
(moxifloxacin)		Studies
(efavirenz)		Trials
(efavirenz)		Recent Studies (post-2010) (efavirenz)
3,1575521,6903,1106311,611

Protein Interaction Comparison

ProteinTaxonomymoxifloxacin (IC50)efavirenz (IC50)
Chain A, POL POLYPROTEINHuman immunodeficiency virus 10.2612
Chain A, POL POLYPROTEINHuman immunodeficiency virus 10.2612
Chain B, POL POLYPROTEINHuman immunodeficiency virus 10.2612
Chain A, POL POLYPROTEINHuman immunodeficiency virus 10.2612
Chain B, POL POLYPROTEINHuman immunodeficiency virus 10.2612
Chain A, Pol PolyproteinHuman immunodeficiency virus 10.2612
Chain B, Pol PolyproteinHuman immunodeficiency virus 10.2612
Prothrombin Bos taurus (cattle)0.022
Gag-Pol polyproteinHIV-1 M:B_HXB2R0.1852
Gag-Pol polyproteinHuman immunodeficiency virus type 1 (NEW YORK-5 ISOLATE)0.02
Kappa-type opioid receptorCavia porcellus (domestic guinea pig)0.018
Microsomal triglyceride transfer protein large subunitHomo sapiens (human)0.054
Disintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)0.004
Envelope glycoprotein gp160 [Cleaved into: Surface protein gp120 Human immunodeficiency virus 10.0035
Reverse transcriptase/RNaseH Human immunodeficiency virus 10.1627
Reverse transcriptase Human immunodeficiency virus 10.0643

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (50.00)24.3611
2020's3 (50.00)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Adamson, J; Chirehwa, M; Denti, P; Essack, S; Govender, K; Kimba-Phongi, E; McIlleron, H; Naidoo, A; Naidoo, K; Padayatchi, N; Yende-Zuma, N1
Badal-Faesen, S; Bryant, K; Campbell, K; Chaisson, RE; Dawson, R; Dooley, KE; Dorman, SE; Fletcher, CV; Johnson, JL; Kurbatova, EV; Lalloo, U; Martinson, N; Mayanja, H; Mohapi, L; Nahid, P; Pettit, A; Pham, M; Phillips, PPJ; Podany, AT; Samaneka, W; Scott, N; Sizemore, E; Swindells, S; Vernon, A; Whitworth, WC1
Bryant, K; Chaisson, RE; Dawson, R; Dooley, KE; Dorman, SE; Johnson, JL; Kurbatova, E; Lalloo, UG; Mohapi, L; Muzanyi, G; Nahid, P; Pettit, AC; Phillips, PPJ; Podany, AT; Samaneka, W; Sanne, I; Savic, RM; Scott, N; Sizemore, E; Swindells, S; Vernon, A; Waja, Z1
Chirehwa, MT; Court, R; De Kock, M; de Vries, N; Denti, P; Gumbo, T; Harding, J; Maartens, G; McIlleron, H; Resendiz-Galvan, JE; Warren, R; Wiesner, L1

Reviews

1 review(s) available for moxifloxacin and efavirenz

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

3 trial(s) available for moxifloxacin and efavirenz

ArticleYear
Effect of rifampicin and efavirenz on moxifloxacin concentrations when co-administered in patients with drug-susceptible TB.
    The Journal of antimicrobial chemotherapy, 2017, 05-01, Volume: 72, Issue:5

    Topics: Adult; Africa; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Benzoxazines; Coinfection; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Fluoroquinolones; HIV Infections; Humans; Male; Moxifloxacin; Reverse Transcriptase Inhibitors; Rifampin; Tuberculosis, Pulmonary

2017
Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022, 09-10, Volume: 75, Issue:4

    Topics: Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; HIV Infections; HIV-1; Humans; Moxifloxacin; Rifampin; Tuberculosis

2022
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349).
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2023, 02-08, Volume: 76, Issue:3

    Topics: Antitubercular Agents; Drug Therapy, Combination; HIV; HIV Infections; Humans; Isoniazid; Moxifloxacin; Rifampin; Tuberculosis; Tuberculosis, Pulmonary

2023

Other Studies

2 other study(ies) available for moxifloxacin and efavirenz

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Optimizing Moxifloxacin Dose in MDR-TB Participants with or without Efavirenz Coadministration Using Population Pharmacokinetic Modeling.
    Antimicrobial agents and chemotherapy, 2023, 03-16, Volume: 67, Issue:3

    Topics: Adult; Alkynes; Antitubercular Agents; Female; Humans; Moxifloxacin; Tuberculosis, Multidrug-Resistant

2023